Profiling placental DNA methylation associated with maternal SSRI treatment during pregnancy

- 3 Amy M. Inkster<sup>A, B</sup>, Chaini Konwar<sup>A, C</sup>, Maria S. Peñaherrera<sup>A, B</sup>, Ursula Brain<sup>A</sup>, Almas Khan<sup>A, E</sup>, E. Magda Price<sup>A, B, F</sup>, Johanna M. Schuetz<sup>A, B</sup>, Élodie Portales-Casamar<sup>A, E</sup>, Amber Burt<sup>G</sup>, 4
- 5
- Carmen J. Marsit<sup>G</sup>, Cathy Vaillancourt<sup>H</sup>, Tim F. Oberlander<sup>A, D\*</sup>, Wendy P. Robinson<sup>A, B\*</sup> 6
- 8 A. BC Children's Hospital Research Institute (BCCHR), Vancouver, BC, V5Z 4H4, Canada.
- 9 B. Department of Medical Genetics, University of British Columbia, Vancouver, BC, V6T 10 1Z3, Canada.
- 11 C. Centre for Molecular Medicine and Therapeutics, Vancouver, BC, V6H 0B3, Canada
- 12 D. School of Population and Public Health, University of British Columbia, Vancouver, BC, 13 V6T 1Z3, Canada.
- 14 E. Department of Pediatrics, University of British Columbia, Vancouver, BC, V6T 1Z4, 15 Canada.
- 16 F. Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, 17 ON, K1H 5B2, Canada.
- 18 G. Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory 19 University, Atlanta, GA, 30322, United States of America.
- 20 H. INRS-Centre Armand Frappier and Réseau intersectoriel de recherche en santé de 21 l'Université du Québec, Laval, QC, H7V 1B7, Canada.
  - \*indicates co-senior authors

## Address all correspondence and requests for reprints to:

- 31 Tim F. Oberlander (toberlander @bcchr.ca) or Wendy P. Robinson, PhD (wrobinson @bcchr.ca)
- 32 BC Children's Hospital Research Institute
- 950 W 28<sup>th</sup> Ave 33

1

2

7

22 23

36 37

- 34 Vancouver, British Columbia
- 35 V5Z 4H4, Canada
  - **Declarations of interest:** none

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

**ABSTRACT Background** Selective serotonin reuptake inhibitors (SSRIs) for treatment of prenatal maternal depression have been associated with neonatal neurobehavioral disturbances, though the molecular mechanisms remain poorly understood. *In utero* exposure to SSRIs may affect DNA methylation (DNAme) in the human placenta, an epigenetic mark that is established during development and is associated with gene expression. Methods Chorionic villus samples from 64 human placentas were profiled with the Illumina MethylationEPIC BeadChip; clinical assessments of maternal mood and SSRI treatment records were collected at multiple time points during pregnancy. Case distribution was 20 SSRI-exposed cases and 44 SSRI non-exposed cases. Maternal depression was defined using a mean maternal Hamilton Depression score >8 to indicate symptomatic depressed mood ("maternallydepressed"), and we further classified cases into SSRI-exposed, maternally-depressed (n=14); SSRI-exposed, not maternally-depressed (n=6); SSRI non-exposed, maternally-depressed (n=20); and SSRI non-exposed, not maternally-depressed (n=24). For replication, Illumina 450K DNAme profiles were obtained from 34 additional cases from an independent cohort (n=17 SSRI-exposed, n=17 SSRI non-exposed). **Results** No CpGs were differentially methylated at FDR < 0.05 comparing SSRI-exposed to non-exposed placentas, in a model adjusted for mean maternal Hamilton Depression score, or in a model

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81 82

83

84

85

restricted to maternally-depressed cases with and without SSRI exposure. However, at a relaxed threshold of FDR < 0.25, five CpGs were differentially methylated ( $|\Delta\beta| > 0.03$ ) by SSRI exposure status. Four were covered by the replication cohort measured by the 450K array, but none replicated. No CpGs were differentially methylated (FDR < 0.25) comparing maternally depressed to not depressed cases. In sex-stratified analyses for SSRI-exposed versus nonexposed cases (females n=31; males n=33), three additional CpGs in females, but none in males, were differentially methylated at the relaxed FDR < 0.25 cut-off. **Conclusions** We did not observe large-scale alterations of DNAme in placentas exposed to maternal SSRI treatment compared to placentas with no SSRI exposure. We also found no evidence for altered DNAme in maternal depression-exposed versus depression non-exposed placentas. This novel work in a prospectively-recruited cohort with clinician-ascertained SSRI exposure and mood assessments would benefit from future replication. **KEYWORDS** Placenta, SSRI, depression, pregnancy, antidepressant, DNA methylation, Illumina EPIC array, sex differences **BACKGROUND** As many as 20% of pregnant individuals suffer from mood disorders such as depression during pregnancy, and up to 6% of all pregnant individuals are treated with antidepressants such as

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

selective serotonin reuptake inhibitors (SSRIs), based on estimates from several North American and European studies (1-4). Clinical management decisions for treatment of perinatal depression are complex, and in each case the clinician must balance the risks of treatment with the severity of depressive symptoms (5). Given the prevalence of maternal depression and SSRI treatment during gestation, much research has been conducted focusing on the fetal effects of both (6,7). Maternal prenatal depressed mood has been associated with preterm birth (< 37 weeks of gestation), growth and developmental delays, and increased postnatal infant stress (8,9). Additionally, the literature suggests that the presence of maternal depressive symptoms independent of SSRI therapy is associated with increases in offspring childhood internalizing behaviours and affective disorders, though these exposures are hard to separate in human studies (10). Animal studies have permitted further investigation into the effect of maternal depressed mood on offspring outcomes by enabling the randomization of SSRI treatment. Rodent models have confirmed that associations identified between maternal depressed mood and offspring anxiety disorders are not mediated by SSRI exposure, and that SSRI treatment does not protect offspring from these outcomes; this topic is reviewed in (10). Regarding the impacts of SSRI treatment on the feto-placental unit, Oberlander et al. previously found that maternal SSRI treatment was associated with altered blood flow to the fetus, increased rates of fetal hypoxemia, altered early neurodevelopment, lower arousal index throughout the newborn period, and altered psychomotor test scores (6,7,11–13). Prenatal SSRI exposure also tended to be associated with lower fetal-placental weight ratios and poorer fetal vascular perfusion, indicative of less efficient fetal blood flow to or from the placenta (14). Both of these

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

factors indicate less efficient placental function in association with prenatal SSRI exposure, which may be related to downstream neonatal cognitive outcomes (14). Exposure to maternal SSRI treatment has previously been reported to affect syncytialization of placental trophoblasts and extravillous trophoblast function, and to affect placental serotonin levels (15–17). Taken together, the effect of SSRI exposure on pregnancy outcomes suggests an interplay between the placenta and SSRI pharmacobiology, which could occur by a variety of mechanisms. It has, however, been postulated that both depression and SSRI exposure may impact fetal outcomes via altered serotonin signalling and downstream effects. Serotonin (5-hydroxytryptamine, or 5-HT) is a central neurotransmitter and a critical signaling factor in many contexts, including during prenatal neurodevelopment of the fetus (18). Low levels of serotonin in the central nervous system have historically been associated with depressive symptoms in adults, in the 5-HT theory of depression (19). SSRI therapeutics, which increase extracellular levels of 5-HT, have been associated with alleviation of depressive symptoms (20). *In vivo*, serotonin is synthesized from the essential amino acid L-tryptophan, by tryptophan hydroxylase enzymes 1 and 2 (TPH-1, TPH-2), and is degraded by monoamine oxidases A and B (MAOA, MAOB) (21,22). SSRIs function to block the serotonin transporter (SERT, also known as 5-HTT (5-hydroxytryptamine transporter)), inhibiting the reabsorption of 5-HT by the presynaptic neurons and thereby increasing extracellular serotonin levels in the central nervous system (13). Several aspects of serotonin and SSRI biology are relevant to prenatal development, and both maternal depression and SSRI exposure have been associated with altered fetal outcomes. Notably, serotonin is first expressed early in gestation, when placental TPH-1 and TPH-2 convert maternal L-tryptophan to serotonin de novo (22,23). Over

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

the course of gestation, serotonin (5-HT) is essential to many processes of prenatal development including embryogenesis, placentation, and neurodevelopment (21,24,25). SSRIs readily cross the placenta, leading to fetal drug exposure and altered fetal cardiac autonomic activity, presumably via altered serotonin signaling in the placenta and/or fetus (26,27). One plausible mechanism by which SSRI exposure may impact pregnancy outcomes is via DNA methylation (DNAme). DNAme is an epigenetic mark involving the addition of a methyl group to the 5' carbon of a cytosine molecule, which usually occurs in the context of cytosine-guanine dinucleotides (CpGs). In human tissues, DNAme signatures are associated with gene expression patterns (28), and are altered in association with certain environmental and chemical exposures, such as air pollution, arsenic, and tobacco smoke; for a review of this topic see (29). DNAme patterns in the human placenta vary in association with certain maternal exposures and environments, but are relatively stable once established and serve as a possible record of gene expression patterns and exposures in gestation (30,31). The placenta exists at the interface of the maternal environment and the developing fetus, and environmental factors can gain access to the fetus in many cases only via the placenta (32,33). As SSRIs readily cross the placenta (34), it is possible that SSRI species alter placental DNAme patterns directly via association with epigenetic readers and writers (DNMT or TET enzymes), or through altering gene expression patterns in the serotonin signalling pathway, or other related pathways (29). In this study, we hypothesized that prenatal SSRI treatment would be associated with distinct placental DNAme signatures. In a prospective cohort of 64 placentas with extensive maternal

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

mood assessments during gestation, both with and without SSRI exposure, we investigated the effects of maternal SSRI treatment and maternal depressed mood on placental DNA methylation profiles. We considered the effect of SSRI exposure on placental DNAme as our primary outcome. The secondary outcome considered was the impact of maternal depression, which was investigated among participants not treated with SSRIs. Additionally, given previously reported sex differences in neurodevelopmental and placental outcomes related to maternal stress (35–40), we also assessed placental DNAme associated with maternal SSRI treatment in separate sexstratified models. **METHODS** Discovery cohort Participants were recruited as part of a prospective, longitudinal cohort approved by the University of British Columbia/Children's and Women's Health Centre of British Columbia research ethics board: H12-00733 (40). Written informed consent was obtained from all participants, and all procedures complied with the ethical standards on human experimentation and with the Helsinki Declaration of 1975 (revised in 2008). This specific study was additionally approved under certificate H16-02280. Pregnant individuals with and without prenatal diagnoses of clinical depression, and with/without SSRI treatment plans were recruited at the British Columbia Women's Hospital (BCWH) in the 20<sup>th</sup> week of gestation (n=64). At recruitment, all pregnant individuals received the MINI assessment to screen for DSM-IV Axis I Depression. SSRI use was reported by the

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

treating clinicians, and was defined as treatment for at least 75 days including the 3<sup>rd</sup> trimester with one of the following: fluoxetine (Prozac), paroxetine (Paxil), sertraline (Zoloft), citalogram (Celexa), escitalopram (Lexapro), or venlafaxine (Effexor). Compliance with SSRI treatment was assessed and recorded at each prenatal study visit. While placental drug concentrations were not available at the time of this study, previous work on this cohort indicated that maternal plasma drug concentrations during gestation were consistent with self-report of SSRI use (26). Maternal mood was assessed at recruitment, 36 weeks of gestation, postnatal day 6, and at 24 months postnatally. The mood assessment included multiple clinician and patient-rated measures, of which the Hamilton Depression score, a 17-item clinician implemented assessment of the severity of depressive symptoms (41), and the Edinburgh Postnatal Depression score (EPDS), a 10-item self-assessment screening tool for depression (42), were analyzed. Exclusion criteria were: bipolar illnesses, hypertension, any diabetes, current substance abuse, placental insufficiency, multi-fetal pregnancies, infants with congenital brain malformations, intrauterine growth restriction, or preterm birth. For all participants, measures of obstetric history, prenatal medication use, and sociodemographic variables were obtained. At birth, additional clinical information was collected for each infant including gestational age at delivery, infant sex assigned at birth, and infant birth weight; placentas were collected for DNAme studies. After delivery, chorionic villus samples were obtained from 4 distinct cotyledonary sites (1.5-2 cm<sup>3</sup>) below the surface of the fetal-facing side of each placenta, as previously described (43). DNA was extracted from each of the 4 sites and pooled in equimolar amounts to provide a representative sample of the whole placenta prior to obtaining DNAme profiles. DNAme data for

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

these 64 cases was collected in a single processing batch using the Illumina MethylationEPIC ("EPIC") array platform (Illumina, San Diego, CA, USA), which profiles >850,000 CpGs genome-wide. Case distribution was as follows: 20 SSRI-exposed and 44 SSRI non-exposed samples (Table 1). Cases were additionally sub-categorized into four groups for analysis based on both SSRI exposure and maternal depression status using a mean maternal Hamilton Depression score of >8 to indicate symptomatic depressed mood ("maternally depressed") as follows: SSRI-exposed, maternally-depressed (n=14); SSRI-exposed without maternal depression (n=6); SSRI nonexposed, maternally depressed (n=20); and SSRI non-exposed without maternal depression (n=24), see Table 2 and Figure 1. Replication cohort An independent cohort of 34 cases with (i) known SSRI-exposure status and (ii) pre-collected placental DNAme data were obtained from a subset of the Rhode Island Child Healthy Study (RICHS) (44). Cohort participants were treated with one of the following SSRIs: fluoxetine, paroxetine (Paxil), sertraline (Zoloft), citalopram (Celexa), or escitalopram (Lexapro). Assessments of maternal mood were not available for these cases. DNAme data for these 34 cases were previously collected with the Illumina HumanMethylation450 ("450K") array platform, and are available on the Gene Expression Omnibus (GEO) repository under accession number GSE75248 (44).

## Table 1. Demographics of the discovery and replication cohorts by SSRI exposure status. SSRI

refers to selective-serotonin reuptake inhibitor treatment during pregnancy. Birthweight Z-

scores were calculated using gestational-age and sex-adjusted birthweight curves (45).

223

224

Naternal Hamilton   20	Discovery Cohort	CCDI 1	N CCDI I	1 1	
Maternal Hamilton   Depression Score (mean (SD))		SSRI-exposed	Non-SSRI-exposed	p value†	
Depression Score (mean (SD))   26 weeks   10.6 (5.4)   6.6 (3.6)   0.001**   36 weeks   10.8 (4.2)   8.3 (3.6)   0.001**   Mean   10.6 (4.5)   7.5 (3.5)   0.004**   Length SSRI exposure (days, mean (SD))   -		20	44		
(SD)) 26 weeks 10.6 (5.4) 6.6 (3.6) 0.001** 36 weeks 10.8 (4.2) 8.3 (3.6) 0.021*  Mean 10.6 (4.5) 7.5 (3.5) 0.004**  Length SSRI exposure (days, mean (SD))  Type of SSRI exposure (n (%)) □  Citalopram 7 (35.0) -  Escitalopram 7 (35.0) -  Fluoxetine 1 (5.0) -  Paroxetine 1 (5.0) -  Sertraline 4 (20.0) -  Delivery type (n vaginal (%)) 10 (50.0) 29 (65.9) 0.351 (weeks, mean (SD))  Gestational diabetes (n, mean (SD))  Gestational diabetes (n, mean (SD))  Infant sex (n male (%)) 8 (40.0%) 25 (56.8%) 0.328 (mean (SD))  PlaNET Ancestry (mean (SD))  Coordinate 1 0.00 (0.00) 0.00 (0.01) 0.354 (Coordinate 2 0.05 (0.21) 0.13 (0.31) 0.300 (Coordinate 3 0.95 (0.21) 0.86 (0.31) 0.286 (Replication Cohort  SSRI-exposed Non-SSRI-exposed p value†  Type of SSRI exposure (n (%)) □					
10.6 (5.4)					
10.8 (4.2)   8.3 (3.6)   0.021*	1 11	10 ( (5 4)	( ( ( ) ( )	0.001**	
Mean   10.6 (4.5)   7.5 (3.5)   0.004**   Length SSRI exposure (days, mean (SD))   -   -		· /	` /		
Length SSRI exposure (days, mean (SD))			\ /		
Type of SSRI exposure (n (%))			7.5 (3.5)	0.004**	
Type of SSRI exposure (n (%))□       Citalopram       7 (35.0)       -       -         Escitalopram       7 (35.0)       -       -         Fluoxetine       1 (5.0)       -       -         Paroxetine       1 (5.0)       -       -         Sertraline       4 (20.0)       -       -         Delivery type (n vaginal (%))       10 (50.0)       29 (65.9)       0.351         Gestational age at birth (weeks, mean (SD))       39.3 (1.4)       39.6 (1.3)       0.438         (weeks, mean (SD))       6       6       0 (0)       -       -         Infant sex (n male (%))       8 (40.0%)       25 (56.8%)       0.328       0.328         Infant birthweight Z-score (mean (SD))       -0.01 (1.00)       -0.03 (0.73)       0.915         (mean (SD))       Coordinate 1       0.00 (0.00)       0.00 (0.01)       0.354         Coordinate 2       0.05 (0.21)       0.13 (0.31)       0.300         Coordinate 3       0.95 (0.21)       0.86 (0.31)       0.286         Replication Cohort         SSRI-exposed       Non-SSRI-exposed       p value†         Type of SSRI exposure (n (%))□       17       17	•	264.4 (29.9)	-	-	
Citalopram       7 (35.0)       -       -         Escitalopram       7 (35.0)       -       -         Fluoxetine       1 (5.0)       -       -         Paroxetine       1 (5.0)       -       -         Sertraline       4 (20.0)       -       -         Delivery type (n vaginal (%))       10 (50.0)       29 (65.9)       0.351         Gestational age at birth (weeks, mean (SD))       39.3 (1.4)       39.6 (1.3)       0.438         (weeks, mean (SD))       6       6       6       0 (0)       -       -         Infant sex (n male (%))       8 (40.0%)       25 (56.8%)       0.328       0.328         Infant birthweight Z-score (mean (SD))       -0.01 (1.00)       -0.03 (0.73)       0.915         PlaNET Ancestry <sup>§</sup> (mean (SD))       0.00 (0.00)       0.00 (0.01)       0.354         Coordinate 1       0.00 (0.00)       0.13 (0.31)       0.300         Coordinate 2       0.05 (0.21)       0.13 (0.31)       0.286         Replication Cohort         SSRI-exposed       Non-SSRI-exposed       p value <sup>†</sup> Type of SSRI exposure (n (%))       17       17	. ,,				
Secitalopram					
Fluoxetine	Citalopram	7 (35.0)	-	-	
Paroxetine         1 (5.0)         -           Sertraline         4 (20.0)         -           Delivery type (n vaginal (%))         10 (50.0)         29 (65.9)         0.351           Gestational age at birth (weeks, mean (SD))         39.3 (1.4)         39.6 (1.3)         0.438           Gestational diabetes (n, mean (SD))         0 (0)         0 (0)         -           Infant sex (n male (%))         8 (40.0%)         25 (56.8%)         0.328           Infant birthweight Z-score (mean (SD))         -0.01 (1.00)         -0.03 (0.73)         0.915           PlaNET Ancestry <sup>§</sup> (mean (SD))         Coordinate 1         0.00 (0.00)         0.00 (0.01)         0.354           Coordinate 2         0.05 (0.21)         0.13 (0.31)         0.300           Coordinate 3         0.95 (0.21)         0.86 (0.31)         0.286           Replication Cohort           SRI-exposed         Non-SSRI-exposed         p value†           Type of SSRI exposure (n (%))	Escitalopram	7 (35.0)	-		
Sertraline	Fluoxetine	1 (5.0)	-		
Delivery type (n vaginal (%))         10 (50.0)         29 (65.9)         0.351           Gestational age at birth (weeks, mean (SD))         39.3 (1.4)         39.6 (1.3)         0.438           Gestational diabetes (n, mean (SD))         0 (0)         0 (0)         -           Infant sex (n male (%))         8 (40.0%)         25 (56.8%)         0.328           Infant birthweight Z-score (mean (SD))         -0.01 (1.00)         -0.03 (0.73)         0.915           PlaNET Ancestry <sup>§</sup> (mean (SD))         (SD))         0.00 (0.00)         0.00 (0.01)         0.354           Coordinate 1         0.05 (0.21)         0.13 (0.31)         0.300           Coordinate 2         0.05 (0.21)         0.86 (0.31)         0.286           Replication Cohort           SSRI-exposed         Non-SSRI-exposed         p value†           17         17           Type of SSRI exposure (n (%)) □         17         17	Paroxetine	1 (5.0)	-		
Gestational age at birth (weeks, mean (SD))         39.3 (1.4)         39.6 (1.3)         0.438           Gestational diabetes (n, mean (SD))         0 (0)         0 (0)         -           Infant sex (n male (%))         8 (40.0%)         25 (56.8%)         0.328           Infant birthweight Z-score (mean (SD))         -0.01 (1.00)         -0.03 (0.73)         0.915           PlaNET Ancestry <sup>§</sup> (mean (SD))         Coordinate 1         0.00 (0.00)         0.00 (0.01)         0.354           Coordinate 2         0.05 (0.21)         0.13 (0.31)         0.300           Coordinate 3         0.95 (0.21)         0.86 (0.31)         0.286           Replication Cohort         SSRI-exposed         Non-SSRI-exposed         p value†           Type of SSRI exposure (n (%)) □         17         17	Sertraline	4 (20.0)	-		
(weeks, mean (SD))         Gestational diabetes (n, mean (SD))         0 (0)         0 (0)         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -         -	Delivery type (n vaginal (%))	10 (50.0)	29 (65.9)	0.351	
Gestational diabetes (n, mean (SD))         0 (0)         0 (0)         -           Infant sex (n male (%))         8 (40.0%)         25 (56.8%)         0.328           Infant birthweight Z-score (mean (SD))         -0.01 (1.00)         -0.03 (0.73)         0.915           PlaNET Ancestry§ (mean (SD))         Coordinate 1         0.00 (0.00)         0.00 (0.01)         0.354           Coordinate 2         0.05 (0.21)         0.13 (0.31)         0.300           Coordinate 3         0.95 (0.21)         0.86 (0.31)         0.286           Replication Cohort         SSRI-exposed         Non-SSRI-exposed $p$ value†           Type of SSRI exposure (n (%)) $^{\circ}$ 17         17	Gestational age at birth	39.3 (1.4)	39.6 (1.3)	0.438	
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	(weeks, mean (SD))				
Infant sex (n male (%))         8 (40.0%)         25 (56.8%)         0.328           Infant birthweight Z-score (mean (SD))         -0.01 (1.00)         -0.03 (0.73)         0.915           PlaNET Ancestry <sup>§</sup> (mean (SD))           Coordinate 1         0.00 (0.00)         0.00 (0.01)         0.354           Coordinate 2         0.05 (0.21)         0.13 (0.31)         0.300           Coordinate 3         0.95 (0.21)         0.86 (0.31)         0.286           Replication Cohort           SSRI-exposed         Non-SSRI-exposed         p value†           Type of SSRI exposure (n (%))□         17         17		0 (0)	0 (0)	-	
Infant birthweight Z-score (mean (SD))         -0.01 (1.00)         -0.03 (0.73)         0.915           PlaNET Ancestry (mean (SD))         0.00 (0.00)         0.00 (0.01)         0.354           Coordinate 1         0.00 (0.00)         0.13 (0.31)         0.300           Coordinate 2         0.05 (0.21)         0.13 (0.31)         0.286           Replication Cohort         SSRI-exposed Non-SSRI-exposed $p$ value†           Type of SSRI exposure (n (%)) (%)) (%)         17	, , , ,				
(mean (SD))         PlaNET Ancestry§ (mean (SD))         Coordinate 1 $0.00 (0.00)$ $0.00 (0.01)$ $0.354$ Coordinate 2 $0.05 (0.21)$ $0.13 (0.31)$ $0.300$ Coordinate 3 $0.95 (0.21)$ $0.86 (0.31)$ $0.286$ Replication Cohort         SSRI-exposed       Non-SSRI-exposed $p$ value†         Type of SSRI exposure (n (%)) $^{\square}$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ <		, , , , , , , , , , , , , , , , , , , ,			
PlaNET Ancestry <sup>§</sup> (mean (SD))         Coordinate 1       0.00 (0.00)       0.00 (0.01)       0.354         Coordinate 2       0.05 (0.21)       0.13 (0.31)       0.300         Coordinate 3       0.95 (0.21)       0.86 (0.31)       0.286         Replication Cohort         SSRI-exposed       Non-SSRI-exposed       p value†         Type of SSRI exposure (n (%))□       17       17		-0.01 (1.00)	-0.03 (0.73)	0.915	
(SD))       0.00 (0.00)       0.00 (0.01)       0.354         Coordinate 2       0.05 (0.21)       0.13 (0.31)       0.300         Coordinate 3       0.95 (0.21)       0.86 (0.31)       0.286         Replication Cohort         SSRI-exposed       Non-SSRI-exposed $p$ value†         Type of SSRI exposure (n (%)) $^{\square}$ 17       17					
Coordinate 1 $0.00 (0.00)$ $0.00 (0.01)$ $0.354$ Coordinate 2 $0.05 (0.21)$ $0.13 (0.31)$ $0.300$ Coordinate 3 $0.95 (0.21)$ $0.86 (0.31)$ $0.286$ Replication Cohort           SSRI-exposed         Non-SSRI-exposed $p$ value†           Type of SSRI exposure (n (%)) $^{\square}$ $(96)$ ) $^{\square}$ $(96)$ ) $^{\square}$	- ·				
Coordinate 2 $0.05 (0.21)$ $0.13 (0.31)$ $0.300$ Coordinate 3 $0.95 (0.21)$ $0.86 (0.31)$ $0.286$ Replication Cohort           SSRI-exposed         Non-SSRI-exposed $p$ value†           Type of SSRI exposure (n (%)) $^{\square}$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$ $(96)$	` //	0.00 (0.00)	0.00 (0.01)	0.274	
Coordinate 3         0.95 (0.21)         0.86 (0.31)         0.286           Replication Cohort         SSRI-exposed         Non-SSRI-exposed $p$ value†           n         17         17           Type of SSRI exposure (n (%)) $^{\square}$ (%)) $^{\square}$ (%)		. ,			
Replication Cohort $ \begin{array}{c ccccccccccccccccccccccccccccccccccc$		. ,	` '		
SSRI-exposed Non-SSRI-exposed $p$ value†  n 17 17  Type of SSRI exposure (n $(\%)$ ) $^{\square}$	Coordinate 3	0.95 (0.21)	0.86 (0.31)	0.286	
n 17 17 $(\%)$ ) $\Box$	<b>Replication Cohort</b>				
Type of SSRI exposure (n (%))		SSRI-exposed	Non-SSRI-exposed	p value†	
<b>(%))</b> <sup>□</sup>	n	17	17		
	Citalopram	3 (17.6)	_	_	

Escitalopram	2 (11.8)	-	
Fluoxetine	2 (11.8)	-	
Paroxetine	1 (5.9)	-	
Sertraline	9 (52.9)	-	
Delivery type (n vaginal (%))	4 (23.5)	12 (70.6)	0.016*
Gestational age at birth	39.0 (0.9)	39.0 (0.9)	0.999
(weeks, mean (SD))			
Infant sex (n male (%))	7 (41.2)	10 (58.8)	0.493
Gestational diabetes (n mean	5 (29.4)	3 (18.8)	0.758
(SD))			
PlaNET Ancestry§			
Coordinate 1	0.00 (0.01)	0.08 (0.25)	0.212
Coordinate 2	0.01 (0.04)	0.12 (0.32)	0.174
Coordinate 3	0.98 (0.05)	0.80 (0.38)	0.057

- 226 †p values are from chi-squared tests for categorical variables and t-tests for continuous variables,
- comparing SSRI-exposed to SSRI non-exposed, \* indicates <0.05, \*\* indicates <0.005.
- 228 §The PlaNET algorithm outputs DNAme-based ancestry probability values ranging from 0-1,
- which sum to 1 for each sample. Coordinate 1 is associated with probability of African ancestry,
- coordinate 2 with East Asian ancestry, and coordinate 3 with European ancestry (46).

Table 2. Discovery cohort demographics by SSRI and depression group status. Maternal depression was categorized using mean maternal Hamilton Depression score,  $\leq 8$  was categorized as not depressed, > 8 as depressed, this is reflected in the "Depression Group" row. SSRI refers to selective-serotonin reuptake inhibitor treatment during pregnancy. Birthweight Z scores were calculated using gestational-age and sex-adjusted birthweight curves (45).

	SSRI-exposed, maternally- depressed	SSRI-exposed, not maternally depressed	SSRI non- exposed, maternally- depressed	SSRI non- exposed, not maternally- depressed	SSRI exposed vs non-exposed p value† (maternally- depressed)	SSRI exposed vs non-exposed p value† (not maternally- depressed)
Depression Group	Depressed	Not depressed	Depressed	Not Depressed	Depressed vs. Depressed	Not Depressed vs. Not Depressed
n	14	6	20	24		
Maternal Hamilton Depression Score (mean (SD))						
26 weeks	13.4 (3.9)	4.5 (2.4)	9.7 (2.6)	4.3 (2.2)	0.003*	0.841
36 weeks	12.8 (2.8)	5.6 (2.6)	11.0 (2.2)	5.8 (2.7)	0.045*	0.869
Mean	13.0 (2.9)	5.2 (1.8)	10.5 (2.2)	5.0 (2.1)	0.009*	0.877
Length SSRI exposure (days, mean (SD))	266.93 (19.28)	258.33 (48.65)	-	-	-	-
Type of SSRI exposure (n (%))						
Citalopram	5 (35.7)	2 (33.3)	-	-	-	-
Escitalopram	5 (35.7)	2 (33.3)	-	-		

Fluoxetine	0 (0.0)	1 (16.7)	-	-		
Paroxetine	1 (7.1)	0 (0.0)	-	-		
Sertraline	3 (21.4)	1 (16.7)	-	-		
Delivery type (n vaginal (%))	5 (35.7)	5 (83.3)	11 (55.0)	18 (75.0)	0.281	0.99
Gestational age at birth (weeks, mean (SD))	39.1 (1.4)	39.7 (1.4)	39.6 (1.3)	39.5 (1.4)	0.447	0.697
Gestational diabetes (n, mean (SD))	0 (0)	0 (0)	0 (0)	0 (0)	-	-
Infant sex (n male (%))	6 (42.9%)	2 (33.3%)	11 (55.0%)	14 (58.3%)	0.727	0.522
Infant birthweight Z- score (mean (SD))	-0.01 (1.06)	0.00 (0.94)	-0.02 (0.62)	-0.05 (0.82)	0.989	0.906
PlaNET Ancestry <sup>§</sup> (mean (SD))						
Coordinate 1	0.00 (0.00)	0.00 (0.00)	0.01 (0.02)	0.00 (0.00)	0.292	0.665
Coordinate 2	0.07 (0.25)	0.01 (0.01)	0.14 (0.32)	0.12 (0.31)	0.488	0.370
Coordinate 3	0.93 (0.25)	0.99 (0.01)	0.85 (0.32)	0.87 (0.31)	0.460	0.369

<sup>†</sup>p values are from chi-squared tests for categorical variables and t-tests for continuous variables, \* indicates <0.05, \*\* indicates

236 < 0.005.

238

p = 0.59 (chi-squared test) for proportion of SSRI types utilized by SSRI-exposed, maternally-depressed participants versus SSRI-exposed,

exposed, not maternally-depressed participants.

- 239 §The PlaNET algorithm outputs DNAme-based ancestry probability values ranging from 0-1, which sum to 1 for each sample.
- 240 Coordinate 1 is associated with probability of African ancestry, coordinate 2 with East Asian ancestry, and coordinate 3 with
- European ancestry (46).

Data processing

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

Processing and normalization of the Illumina EPIC DNAme data for the discovery cohort is described in full in the Supplementary Methods. First, sample sex (XY chromosome complement) and genetic uniqueness were assessed and confirmed to match the annotated metadata. Next, polymorphic and cross-hybridizing probes were removed from this dataset (47), as were probes with a detection p value > 0.01 in > 5% of cases. Subsequently, CpGs with nonvariable DNAme in this cohort (n=87,572) were removed from the dataset to decrease multiple test correction burden. Non-variable CpGs were defined as in (48) as CpGs that met both of the following conditions: (i) < 5% range in DNAme beta (β) values between the 10<sup>th</sup>-90<sup>th</sup> centile, and (ii) previously reported as placenta-non-variable in (49). After processing and dasen + noob normalization (50), 659,036 autosomal CpGs in 64 cases plus 8 pairs of technical replicates remained for analysis. The technical replicates were used to estimate an absolute delta beta ( $|\Delta\beta|$ ) cut-off for subsequent analyses, based on the average root mean squared error of the technical replicate pairs (0.026) and the average standard error of all CpGs in all cases (0.0048). The highest of these values was selected and rounded up, to establish a  $|\Delta\beta|$  cut-off of > 0.03 between groups; anything less than  $|\Delta\beta| = 0.03$  could represent technical noise and was unlikely to be biologically meaningful in this cohort. After processing, the replicate pairs were removed from the cohort and excluded from downstream analysis. Batch correction was performed after identifying an effect of EPIC array row on DNAme data using Principal Components Analysis, see Supplementary Figure S1. Prior to batch correction, the distribution of cases across EPIC array rows was confirmed to be independent of our primary outcomes of interest: SSRI status (Fisher test p > 0.05) and mean maternal Hamilton depression

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

score (ANOVA p > 0.05), see Supplementary Figure S2. ComBat was used to correct the remaining categorical effect of the "row" variable, with SSRI exposure (yes/no) and mean maternal Hamilton Depression score (continuous) included as variables of interest in the ComBat model matrix as recommended by the sva package authors (51). Results for batch-corrected analyses were confirmed in non-batch-corrected data to ensure that false signal was not introduced during batch correction, in accordance with the recommendations outlined in (52), see Supplementary Figure S1. Replication cohort The raw data for the full 335-sample RICHS cohort was downloaded from GEO (GSE75248) and processed analogously to the discovery cohort: first sample sex and genetic uniqueness were checked, data were dasen + noob normalized, and polymorphic and cross-hybridizing probes were removed (47), as were probes with a detection p value > 0.01 in > 5% of cases. For a complete description of data processing see the Supplementary Methods. The processed data were subsetted to 34 cases for which gestational SSRI treatment status was recorded in the medical chart. Replication cohort demographics are presented in Table 1. Covariate selection We next sought to identify characteristics that could be associated with SSRI exposure in the discovery and replication cohorts, and that should be included as covariates in statistical models. Demographic variables considered include those presented in Table 1 and Table 2. The discovery cohort was well-balanced across all demographic variables by both SSRI exposure and maternal depression status. Gestational age, infant sex, and PlaNET ancestry were selected for inclusion as

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

additive covariates in linear modelling analyses as it is known that these factors drive large amounts of DNAme variation in the placenta (46,53). The same variables were selected in the replication cohort (infant sex, gestational age at birth, PlaNET ancestry), with the addition of type of delivery (vaginal/other), as delivery type frequency differed by SSRI exposure in the replication cohort only, see Table 1. Using tools from the *PlaNET* R package (54,55), we also estimated additional variables in the discovery cohort from the DNAme data itself: the proportion of six major placental cell types (cytotrophoblasts, syncytiotrophoblasts, endothelial cells, stromal cells, Hofbauer cells, and nucleated red blood cells), and placental epigenetic age. Cell type proportions were not significantly associated with either SSRI treatment or mean maternal Hamilton Depression score across gestation (t-test for cell type proportions ~ SSRI exposed (yes/no), all p values > 0.05; Pearson correlation for mean maternal Hamilton Depression score and each cell type proportion, all p values > 0.05), see Supplementary Figure S3. Accordingly, cell type proportions were not included as covariates in subsequent linear models. Epigenetic age acceleration was calculated as the residual of the Control Placental Clock epigenetic age regressed on gestational age at birth, adjusted for sex, ancestry, and EPIC array row. Intrinsic epigenetic age acceleration (cell-type independent) was calculated similarly, but with additional adjustment for numeric cell type proportions. Placental epigenetic age was not considered as a possible covariate in linear models, but was analyzed separately for associations with SSRI exposure, as previous cord blood studies have reported conflicting relationships between cord blood epigenetic age acceleration and SSRI treatment, so parallel exploration in the placenta was warranted (56,57), see Results.

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330


331

332

333

Linear modelling to identify placental DNAme associated with SSRI exposure and maternal depression To identify differential DNAme associated with both SSRI exposure and exposure to maternal depression in the discovery cohort, three linear models were explored, see Figure 1. Linear modelling on M values was conducted using *limma* in R (58,59). In addition to the main effects, all models were adjusted for infant sex, gestational age at birth (in weeks), EPIC array row, and two of three PlaNET ancestry coordinates (46); EPIC array row was included as a covariate according to the recommended implementation of ComBat per the sva package authors (51). In (A) the SSRI model, the full cohort was used for a linear model to assess the effect of SSRI exposure ( $n_{exposed} = 20$  versus  $n_{non-exposed} = 44$ ) on placental DNAme, adjusting for mean maternal Hamilton Depression score across gestation. In (B) the SSRIs in maternal depression model, we used only cases with maternal depression (mean maternal Hamilton Depression score > 8, n=34) and assessed the effect of SSRI exposure in exposed (n=14) versus SSRI non-exposed cases (n=20). In (C) the maternal depression without SSRIs model, we used only cases without SSRI exposure during gestation (n=44), and assessed the effect of maternal depression alone by comparing SSRI non-exposed, maternally-depressed cases (n=20) to not maternally-depressed cases (n=24). Multiple test correction for all models was performed using the Benjamini-Hochberg false discovery rate method (60). For replication analyses, linear models were run only on the CpGs of interest (M values), identified in the discovery cohort models A-C. Replication linear models were adjusted for infant sex, gestational age at birth, two of three PlaNET ancestry coordinates, and type of delivery

- (vaginal/other). CpGs were considered to replicate differential DNAme in association with SSRI
- exposure at a nominal p value < 0.05 in the replication cohort.



339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

Figure 1. Comparisons for analysis of differential DNAme associated with SSRI exposure and maternal depression in the discovery cohort. (A) The SSRI model investigates SSRI exposure in the full cohort (n=64), comparing SSRI-exposed (n=20) to SSRI non-exposed (n=44) cases, adjusting for mean maternal Hamilton Depression score across gestation. (B) The SSRIs in maternal depression model investigates SSRI exposure in all maternally-depressed cases (mean maternal Hamilton Depression score >8, n=34), this model compares SSRI-exposed, maternally depressed cases (n=14) to SSRI non-exposed, maternally depressed cases (n=20). (C) The maternal depression without SSRIs model investigates the effect of maternal depression in cases not exposed to SSRIs (n=44), this model compares SSRI non-exposed, maternally depressed cases (n=20) to SSRI non-exposed and not maternally depressed cases (n=24). RESULTS SSRI exposure and maternal depression are not associated with widespread alterations in placental DNAme patterns First, we assessed in separate models whether DNAme was altered in placentas with SSRI exposure or exposure to maternal depression during gestation. No CpGs were significantly differentially methylated at the commonly used statistical threshold of FDR < 0.05 in any of the three models tested. Plotting FDR against the  $|\Delta\beta|$  for all CpG sites tested in the three models demonstrated very few DNAme associations with either SSRI exposure or maternal depression array-wide, see Figure 2.




Figure 2. Volcano plots for differential DNAme in association with SSRI exposure and categorical depression. For all plots HamD refers to the mean maternal Hamilton Depression score across gestation for each individual. False discovery rate (FDR) is shown along the Y axis with more significant (lower FDR) values at the top of the plot. Vertical dashed intercepts demarcate  $|\Delta\beta| = 0.03$ , horizontal dashed intercepts indicate from top to bottom FDR = 0.05, FDR = 0.15, and FDR = 0.25 (A) Volcano plot for the SSRI model, investigating differential DNAme associated with SSRI exposure adjusted for mean maternal HamD score, (n=64). Difference in DNAme ( $\Delta\beta$ ) is plotted along the X axis and was calculated as  $\Delta\beta = \beta_{SSRI-exposed} - \beta_{SSRI-exposed} -$ 

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

 $\beta_{SSRI \text{ non-exposed.}}$  (B) Volcano plot for the SSRIs in maternal depression model, differential DNAme associated with SSRI exposure in cases with mean maternal HamD score > 8, (n=34). Difference in DNAme ( $\Delta\beta$ ) is plotted along the X axis and was calculated as  $\Delta\beta = \beta_{SSRI-exposed}$  – B<sub>SSRI non-exposed</sub>. (C) Volcano plot for the maternal depression without SSRIs model, differential DNAme associated HamD score > 8 across gestation, in SSRI non-exposed cases, (n=44). Difference in DNAme ( $\Delta\beta$ ) is plotted along the X axis and was calculated as  $\Delta\beta = \beta_{\text{Hamilton} > 8}$  $\beta_{\text{Hamilton}} \leq 8$ . Since the relatively small sample size of the discovery cohort could limit our ability to detect significant between-group DNAme differences, in addition to the standard threshold of FDR < 0.05, we also evaluated CpGs that met more relaxed thresholds of FDR < 0.15 and FDR < 0.25. As these thresholds are associated with increased expected proportions of false positive findings, we have labelled FDR < 0.15 hits "moderate-confidence" and FDR < 0.25 "low-confidence". For both FDR < 0.15 and FDR < 0.25 thresholds, we maintained a minimum effect size threshold of  $|\Delta\beta| > 0.03$ . At these relaxed thresholds, in the SSRI model (model A) adjusted for mean maternal Hamilton Depression score, one CpG was differentially methylated at FDR < 0.15, and one more at FDR < 0.25, see Figure 2 and Supplementary Table S1. The one differentially methylated CpG at FDR < 0.15 (cg12900404) exhibited a  $\Delta\beta$  of +0.11 (higher average DNAme  $\beta$  value in SSRI-exposed placentas). Loosening the threshold to FDR < 0.25, one additional CpG was differentially methylated by SSRI exposure status (cg20877313), and was also more highly methylated in SSRI-exposed placentas ( $\Delta\beta$ =+0.04). In the SSRIs in maternal depression model (model B),

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

three CpGs were differentially methylated at the moderate-confidence threshold of FDR < 0.15 (cg12655501, cg26993610, cg14340829). These CpGs all had an average difference in DNAme between SSRI-exposed and SSRI non-exposed cases of  $|\Delta\beta| > 0.10$ . In the maternal depression without SSRIs model (model C), no CpGs showed evidence of maternal depression-associated differential DNAme at any FDR threshold. For a description of all CpGs that satisfied the moderate and low-confidence FDR thresholds from the SSRI models (A, B) and SSRIs in maternal depression model (C), including test statistics and overlapping genes, see Table 3. Summary statistics of linear modelling from all CpGs tested are presented in Supplementary Tables S2-S4. Boxplots showing average DNAme β values in SSRI-exposed versus SSRI nonexposed cases for the differentially methylated CpGs are shown in Figure 3. A differentially methylated region (DMR) analysis was also conducted, to increase power for discovering DNAme-associations by grouping signatures from multiple neighboring CpG sites to reduce the number of statistical comparisons. DMR analysis was only conducted for the SSRI model to enable utilization of the entire cohort of cases and maximize statistical power. M values were assessed for being part of DMRs for which average DNAme differed by SSRI exposure status using the *DMRcate* R package (FDR < 0.25, lambda = 1000, C = 2) (61). Only one DMR was identified with an average DNAme β value that differed by SSRI exposure, this DMR comprised of two CpGs 70 base pairs apart (cg06762403 and cg14921691) on chromosome 12, overlapping the *DGKA* gene. The average  $\Delta\beta$  across the region was +0.06, indicating higher DNAme in SSRI-exposed placentas, see Table 3 and Supplementary Figure S4.

Table 3. Top CpGs with differential DNAme by SSRI-exposure status. Linear modelling p value and false discovery rates (FDR) shown,  $\Delta \beta$  is difference in DNAme calculated as  $\Delta \beta = \beta_{SSRI-exposed} - \beta_{SSRI\ non-exposed}$ . hg19 chromosome (Chr) and coordinates (Position) for each CpG are indicated, as are genes that each CpG overlaps, and whether each CpG is covered by a probe on the 450K DNA methylation array. A and B in the Model Column refer to model A and model B, DMR refers to the differentially-methylated region analysis.

Model	CpG	p value	FDR	FDR threshold	Δβ	Chr:Position	Gene Symbol	Relation to Gene	450K locus?
A	cg12900404	9.11e- 08	0.06	Moderate confidence	0.11	2:225811669	DOCK10	1 <sup>st</sup> Exon	-
A	cg20877313	6.05e- 07	0.20	Low confidence	0.04	12:56881753	GLS2	1 <sup>st</sup> Exon	Yes
В	cg12655501	6.07e- 07	0.14	Low confidence	0.12	1: 115603524	TSPAN2	Body	-
В	cg26993610	6.26e- 07	0.14	Low confidence	0.14	1:115605466	TSPAN2	Body	-
В	cg14340829	1.80e- 07	0.12	Low confidence	0.10	8:923973	-	-	Yes
DMR	cg14921691, cg06762403	-	1.95e- 29	-	0.06	12: 56325797- 56325867	DGKA	5'UTR, 1 <sup>st</sup> Exon	Yes




Figure 3. Boxplots of differentially methylated CpGs by SSRI exposure. For all plots, points are colored by SSRI exposure (blue = SSRI non-exposed, dark yellow = SSRI-exposed), and boxplots indicate mean DNAme  $\beta$  value  $\pm$  one standard deviation. (A) Boxplot of cg12900404, identified in the SSRI model, model A. (B) Boxplot of cg20877313, identified in the SSRI model, model A. (C) Boxplot of cg12655501, identified in the SSRIs in maternal depression model, model B. (D) Boxplot of cg26993610, identified in the SSRIs in maternal depression model, model B. (E) Boxplot of cg14340829, identified in the SSRIs in maternal depression model, model B.

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

Few placental DNAme differences associated with SSRI exposure in sex-stratified models As the effects of SSRI exposure might differ by sex, we next sought to assess whether unique SSRI-exposure DNAme associations arose in placentas of male versus female infants. Sexstratified linear models were run in males (n=33, 24% SSRI-exposed) and females (n=31, 39%) SSRI-exposed) to test for SSRI-exposure associated DNAme, adjusting for mean maternal Hamilton Depression Score, gestational age at birth, EPIC array row, and PlaNET ancestry. At an FDR < 0.25 and  $|\Delta\beta| > 0.03$ , no CpGs were differentially methylated by SSRI exposure in males. In females, at an FDR < 0.25 and  $|\Delta\beta|$  > 0.03, three CpGs (cg15849349, cg07481545, and cg03905236) were differentially methylated in association with SSRI exposure (Supplementary Figure S5). We previously identified 162 CpGs with robust sex differences in placental DNAme patterns that replicated in an independent dataset (62). To investigate sex in another context, we tested whether these previously-ascertained sex-differentially-methylated CpGs were also differentially methylated by SSRI exposure status. All 162 replicated CpGs were considered, and were subjected to linear modelling in the discovery cohort for SSRI exposure, adjusting for mean maternal Hamilton Depression Score, gestational age at birth, EPIC array row, and PlaNET ancestry. No CpGs met significance at FDR < 0.05. At the low-confidence FDR < 0.25 threshold, three CpGs (cg22515303, cg27003571, cg26136722) had lower DNAme in SSRIexposed placentas than non-exposed placentas, in addition to the previously identified sex effect at these loci (Supplementary Figure S6).

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

No replication of DNAme signature associated with SSRI exposure in an independent dataset We next intended to assess the reproducibility of the five CpGs with SSRI-associated differential DNAme identified in the SSRI model and SSRIs in maternal depression model (Table 3), and the two DMR CpGs. As the replication cohort was run on the Illumina 450K array, only four of these seven discovery cohort CpGs could be assessed for replication (cg14340829, cg20877313, cg06762403, cg14921691). A linear model was applied to the M values from these four CpGs in the replication cohort to test for differential DNAme associated with SSRI exposure, adjusting for infant sex, gestational age at birth, mode of delivery, and PlaNET ancestry. None of the four CpGs replicated differential methylation at a nominal p value < 0.05 in the replication dataset, see Supplementary Figure S7. Placental epigenetic age acceleration not associated with SSRI exposure or maternal depression Epigenetic age is a useful dimension-reduction technique to analyze relationships between global DNAme patterns and a variety of health outcomes. Altered epigenetic age relative to chronological age ("epigenetic age acceleration") has been associated with several negative health outcomes including overall greater burden of disease and higher rates of all-cause mortality (63,64). Specific to depression, major depressive disorder is associated with increased epigenetic age acceleration in adult blood (65). Umbilical cord blood epigenetic age deceleration was initially reported in maternal depression (56), but interestingly this association has since been demonstrated to be largely related to the confounding signature of maternal SSRI treatment rather than depression itself (57).

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

Using a recently published placental epigenetic clock (55), we calculated epigenetic age acceleration in the discovery cohort. We then tested for associations between epigenetic age acceleration metrics and either SSRI exposure or mean maternal Hamilton Depression score using linear models. Neither epigenetic age acceleration nor intrinsic epigenetic age acceleration (cell-type independent) were significantly associated with either SSRI exposure or maternal depression, see Supplementary Figure S8. Replication of previously reported differential methylation candidates associated with SSRIexposure and maternal depression in the discovery cohort A previous study identified 16 CpGs with altered placental DNAme associated with maternal depression (treated as a categorical variable, where depression was maternal EPDS > 10) at FDR < 0.05 (no  $|\Delta\beta|$  threshold) (66). EPDS measurements were also collected for the discovery cohort cases in our study, and were significantly collinear with mean maternal Hamilton Depression scores across gestation, see Supplementary Figure S9. To assess whether these previouslyreported CpGs were also differentially methylated in association with maternal EPDS in the discovery cohort, we ran a linear model on the DNAme M values from these 16 CpGs, adjusting for infant sex, gestational age at birth, ancestry, and EPIC array row. One CpG (cg06670742) satisfied a nominal p value < 0.05 in our cohort, and had higher DNAme in cases with higher mean maternal EPDS scores (FDR < 0.05,  $\Delta\beta$ =+0.003). Thus, differential DNAme of this CpG did replicate in our study, however the effect size in our cohort was very small and does not exceed the technical threshold we set of  $|\Delta\beta| > 0.03$  (Figure 4).

500

501

502

503

504

505

506

507

508

509

510

511

512

513

Three previous studies investigated genome-wide DNAme alterations associated with SSRI treatment in a prenatal tissue (cord blood). An early study by Non et al. (2014) found no association between SSRI exposure and cord blood DNAme at any CpG loci (67). Cardenas et al. (2019) reported one differentially methylated CpG in the gene body of ZNF575 associated with maternal antidepressant treatment in a cohort of cord blood samples (68). In a different cohort, Kallak et al. (2021) reported 13 CpGs differentially methylated by SSRI exposure status in cord blood (69). Though cord blood DNAme is very distinct from placenta, we sought to evaluate whether any of the 14 CpGs reported by Cardenas et al. (68) or Kallak et al. (69) were also differentially methylated by SSRI exposure status in the placenta. At the CpG reported by Cardenas et al. (cg22159528) we found no difference in DNAme by SSRI exposure (nominal p value > 0.05), see Figure 4. At one of the 13 CpGs reported by Kallak et al., we found nominally significant (p < 0.05) differential DNAme associated with SSRI exposure status in the placenta in the same direction as the original cord blood association: higher DNAme in SSRI-exposed cases. This was cg00331486 in LOC284930 on chromosome 22, which encodes a MYCinteracting long noncoding RNA species (69).




Figure 4. Assessment of literature candidates for SSRI and depression-associated DNAme in the discovery cohort. (A) Scatterplot showing the association between DNAme and maternal Edinburgh Postnatal Depression Score (EPS) at cg06670742 which was previously found to be differentially methylated in association with maternal EPDS score in Tesfaye et al. (2021) (37) and is differentially methylated by SSRI exposure at FDR < 0.05 in our discovery cohort. DNAme  $\beta$  value at this CpG is plotted along the Y axis, mean maternal EPDS score is plotted along the X axis and each point is a case;  $\Delta\beta$  per unit increase in EPDS is  $\Delta\beta$ =+0.003. (B) Boxplot showing mean DNAme  $\beta$  value  $\pm$  one standard deviation by SSRI exposure status at cg22159628 in ZNF575, previously found to be differentially methylated in cord blood with

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

antidepressant exposure. Linear modelling p value = 0.67, points are colored by SSRI exposure (blue = SSRI non-exposed, dark yellow = SSRI-exposed), n.s. = not significant. (C) Boxplot showing mean DNAme  $\beta$  value  $\pm$  one standard deviation by SSRI exposure status at cg00331486 in LOC284930 on chromosome 22, previously found to be differentially methylated in cord blood by SSRI exposure status. **DISCUSSION** In this study, we examined genome-wide placental DNAme patterns associated with SSRI exposure or maternal depression during gestation. Taken together, our results suggest the absence of a major impact of SSRI antidepressant exposure on the placental DNA methylome. Specifically, we found no differentially methylated CpGs associated with either SSRI exposure or maternal depression that met the standard significance threshold of FDR < 0.05. These results hold despite known alterations elicited by SSRIs to maternal gestational serotonin signalling and infant outcomes, suggesting that the effects of SSRI exposure on infant outcomes are not associated with a coincident DNAme signature in the placenta. At more relaxed statistical thresholds, differential DNAme analysis highlighted five CpGs associated with SSRI exposure status. Three of the five differentially methylated CpGs overlapped the following genes, respectively: *DOCK10* (CpG not present in replication cohort), GLS2 (CpG did not replicate), and TSPAN2 (CpG not present in replication cohort). The DOCK10 gene encodes the Dopamine Receptor Interacting Protein (70), and was recently found to be one of the twelve most predictive mRNA biomarkers of depression in a gene expression study of adult whole blood (71). These researchers identified that *DOCK10* expression was

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

higher in association with a more positive, less depressed mood (71). DOCK10 is also a target of increased expression by the action of the antidepressant ketamine(71). TSPAN2 encodes Tetraspanin-2, which mediates signal transduction in processes related to cellular growth and development (72). Tspan2 has been reported to be upregulated in the rat hippocampus after chronic exposure to the SSRI fluoxetine (73). We also identified one differentially methylated region in the 5' untranslated region of *DGKA*, with higher DNAme in SSRI exposed placentas. DGKA encodes a diacylglycerol kinase that is involved in intracellular signalling (74), and DGKA activity was recently reported to be inhibited by Ritanserin, a pharmaceutical serotonin receptor type 2 (5-HTR2) antagonist that is not currently in clinical use (75). Inherent to studying the impact of SSRI exposure are the concurrent, and potentially confounding, effects of maternal mood disturbances. As such, studies must be carefully designed to interrogate the effects of either SSRI treatment or depression exposure while accounting for the other factor. Only a limited placental DNAme signature has so far been associated with maternal mood disorders (66), and no work has been conducted to our knowledge interrogating genome-wide placental DNAme signatures associated with SSRI exposure. Tesfaye et al. (66) investigated placental DNAme in association with maternal depression, though SSRI treatment or antidepressant use was not reported on or investigated and could underlie some of these associations. Of the 16 CpGs they identified as differentially methylated by maternal depression status across six gestational time points, only one CpG in the EPS15L1 gene was also differentially methylated our study by mean maternal EPDS score across gestation (FDR < 0.05), and although the effect was in the same direction, the effect size ( $\Delta\beta = +0.003$  with each unit

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

increase in mean EPDS) was well below our biological  $|\Delta\beta|$  threshold of > 0.03, and therefore may not be a biologically meaningful change in DNAme. In non-placental tissue, Kallak et al. (69) identified 13 CpGs that were differentially methylated in cord blood in association with SSRI exposure, one of which replicated at nominal significance in the same direction (higher DNAme in SSRI-exposed cases) in our cohort. Cardenas et al. also identified one CpG in the gene body of ZNF575 (cg22159528) with lower DNAme in antidepressant-exposed cord blood samples from Project Viva, which they replicated in an external cohort (Generation R Study) (68). In our cohort, placental DNAme at this CpG was not associated with SSRI exposure. Although cord blood and placenta are both conceptus-derived tissues relevant to prenatal development and early life, they have unique origins (embryonic versus extraembryonic lineages, respectively) and thus distinct DNAme profiles are expected. Our finding that cord blood differential DNAme does not replicate at high rates in the placenta may suggest a cord-blood-specific DNAme signature at these CpGs in association with maternal SSRI treatment. In sex-stratified analyses, three CpGs were differentially methylated by SSRI exposure in females: two in intergenic regions on chromosomes 4 and 6 respectively, and one in the 5' untranslated region of the SH3GL3 gene. SH3GL3 encodes the Endophilin-A3 protein, which interacts selectively with the Huntingtin protein to promote the formation of polyglutaminecontaining protein aggregates (76). Promoter DNA methylation of the SH3GL3 gene was previously inversely correlated with its expression in human colon cancer cell lines versus matched double knockout cell lines for DNMT1 and DNMT3b (77). Lower DNAme upstream of

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

the promoter of the SH3GL3 gene in SSRI-exposed female placentas may indicate higher expression of this gene relative to the placentas from SSRI non-exposed females, which should be followed up in future work. In a second sex-focused analysis we tested whether previously reported sex-biased CpGs (62) were differentially methylated by SSRI status, three CpGs met the low-confidence FDR < 0.25 threshold (two in the 5' untranslated region of GTDC1, one in the gene body of C14orf132). Together, these analyses suggest that there may be a sex-biased signature of SSRI treatment on the placental DNA methylome or transcriptome, and future studies in this field should be designed to analyze sex as a variable of interest. The major strength of our study lies in the curation of both SSRI treatment and maternal depression information per participant. This prospective design enabled us to investigate the potential confounding effects of these two variables in controlled contexts (i.e. studying SSRI exposure while adjusting for depression scores, and studying the effect of maternal depression in SSRI non-exposed samples). Additionally, in this study we measured genome-wide DNAme in an effort to reduce bias that arises from candidate gene or CpG pyrosequencing studies, and utilized the most modern Illumina EPIC array platform to capture the highest resolution data currently afforded by a DNAme microarray. Further strengths of our study include strict effect size and significance thresholds, the presence of an external replication cohort, the ability to account for covariates such as genetic ancestry and cell type proportions, and the ability to stratify analyses by sex. Limitations of this work include SSRI exposure being defined as maternal treatment with any of six different SSRIs during gestation. It is possible that the SSRI subtypes have different effects

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

on placental DNAme, though this study was not able to undertake sub analysis by SSRI type, and future work should consider this. The extent to which SSRI treatment improves maternal depression scores (i.e. remittance of symptoms) may also be associated with placental DNAme patterns and should be investigated in future longitudinal cohorts. Lastly, although sample size was relatively small, our cohort is among one of a handful of prospectively recruited cohorts that we are aware of with placental tissue collected alongside maternal depression and SSRI treatment information, including the BASIC and Generation R Studies (78,79). Cord blood DNAme data exists for both of these cohorts and has previously been studied in association with maternal SSRI exposure (68,69). Cohorts such as these, with extensive clinical records of maternal mood and medication use across gestation are incredibly valuable resources to investigate how depression status and antidepressant medications may interact with fetal outcomes. In conclusion, our work demonstrates that limited placental DNAme alterations are associated with maternal SSRI exposure; this work agrees with earlier findings of a similarly limited placental DNAme signature of maternal depression. Future work in larger cohorts will determine whether other molecular alterations may co-exist with maternal mood disorders or SSRI treatment, such as altered placental gene expression patterns. As larger cohorts with clinical characterization of maternal SSRI treatment and prenatal depressed mood become available, genetic sequence variation, gene expression patterns, and DNA methylation alterations should all be considered, as well as their interactions.

638

639

640

641

642

643

644

645

646

647

648

649

650

651

652

653

654

655

656

657

658

659

**DECLARATIONS Data availability statement** The raw and preprocessed EPIC array data and corresponding sample metadata supporting the conclusions of this article are available on the Gene Expression Omnibus (GEO), under the accession number GSE203396. Ethics approval and consent to participate Participants were recruited as part of a prospective, longitudinal cohort approved by the University of British Columbia Children's and Women's Health Centre of British Columbia Research Ethics Board (UBC C&W REB) (H12-00733 (40)), this sub study was also approved by the same ethics boards (H16-02280). **Competing interests** The authors declare that they have no competing interests. **Funding** This work was supported by a grant from the National Institutes of Health (1R01HD089713-01). Collection of the Discovery Cohort was funded by a Canadian Institutes of Health Research grant (MOP-5783). WPR receives salary support through an investigatorship award from the BC Children's Hospital Research Institute. AMI is funded by a Frederick Banting and Charles Best Canada Doctoral Scholarship from the Canadian Institutes of Health Research. **Authors' contributions** 

AMI conducted the analyses and wrote the manuscript, and contributed to sample processing, quality control, and testing. CK conducted a preliminary analysis of the effect of SSRI exposure on an earlier version of this data, and contributed to sample processing, quality control, and testing. MSP is the NIH project manager, curated and organized clinical data, contributed to sample processing, quality control, and testing, and manuscript editing. UB conducted clinical data collection. AK processed and normalized the discovery cohort EPIC array data. EMP and JMS were involved in data management, sample metadata collation and establishment of the RedCap database, and participated in randomization. ÉPC oversaw project administration and data curation of this cohort. AB performed data curation for the RICHS cohort cases, CJM is cohort owner of the RICHS data and organized data curation for this set of cases. CV contributed to the conceptualization and design of this project, and also contributed to funding acquisition. TFO and WPR were responsible for project administration, funding acquisition, and supervision of the SSRI cohort recruitment and the DNAme data generation aims of the project, respectively, and were major contributors in writing and revising the manuscript. TO designed the original study. AMI, CK, MSP, UB, AK, EMP, JMS, ÉPC, CV, TFO, and WPR all participated in experimental design. All authors read, revised, and approved the final version of the manuscript.

## Acknowledgements

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

We acknowledge all cohort owners and collaborators on the "Using 'omics to build an atlas of placental development and function across pregnancy" (NIH Project). Thank you to Dr. Michael S. Kobor and the BCCHRI Microarray Core Facilities for support with Illumina EPIC DNAme runs. We thank Robinson lab members Ruby Jiang, Giulia F. Del Gobbo, and Desmond Hui for their work in sample processing, quality control, and testing, thank you to Victor Yuan and Ziqi

- 683 Liu for pilot data processing for cases from this cohort. Finally, we sincerely thank the pregnant
- individuals and families that contributed placental samples to this study.

## REFERENCES

685

686

- Andersson L, Sundström-Poromaa I, Bixo M, Wulff M, Bondestam K, åStröm M. Point prevalence of psychiatric disorders during the second trimester of pregnancy: a population-based study. Am J Obstet Gynecol. 2003 Jul;189(1):148–54.
- 690 2. Gorman LL, O'Hara MW, Figueiredo B, Hayes S, Jacquemain F, Kammerer MH, et al. Adaptation of the structured clinical interview for DSM-IV disorders for assessing depression in women during pregnancy and post-partum across countries and cultures. Br J Psychiatry Suppl. 2004 Feb;46:s17-23.
- Melville JL, Gavin A, Guo Y, Fan MY, Katon WJ. Depressive disorders during pregnancy: prevalence and risk factors in a large urban sample. Obstet Gynecol. 2010 Nov;116(5):1064–70.
- 4. Tran H, Robb AS. SSRI use during pregnancy. Semin Perinatol. 2015 Nov 1;39(7):545–7.
- 5. Kim DR, O'Reardon JP, Epperson CN. Guidelines for the Management of Depression During Pregnancy. Curr Psychiatry Rep. 2010 Aug;12(4):279–81.
- 6. Hanley GE, Oberlander TF. The effect of perinatal exposures on the infant: Antidepressants and depression. Best Pract Res Clin Obstet Gynaecol. 2014 Jan 1;28(1):37–48.
- 701 7. Hanley GE, Brain U, Oberlander TF. Prenatal exposure to serotonin reuptake inhibitor 702 antidepressants and childhood behavior. Pediatr Res. 2015 Aug;78(2):174–80.
- Goodman SH, Halperin MS. Perinatal depression as an early stress: Risk for the development of psychopathology in children. In: The Oxford handbook of stress and mental health. New York, NY, US: Oxford University Press; 2020. p. 287–312. (Oxford library of psychology).
- 706 9. Talge NM, Neal C, Glover V, Early Stress, Translational Research and Prevention Science Network: Fetal and Neonatal Experience on Child and Adolescent Mental Health. Antenatal maternal stress and long-term effects on child neurodevelopment: how and why? J Child Psychol Psychiatry. 2007 Apr;48(3–4):245–61.
- Hutchison SM, Mâsse LC, Pawluski JL, Oberlander TF. Perinatal selective serotonin reuptake
   inhibitor (SSRI) and other antidepressant exposure effects on anxiety and depressive behaviors in
   offspring: A review of findings in humans and rodent models. Reprod Toxicol Elmsford N. 2021
   Jan;99:80–95.
- 714 11. Oberlander T, Gingrich J, Ansorge M. Sustained Neurobehavioral Effects of Exposure to SSRI
   715 Antidepressants During Development: Molecular to Clinical Evidence. Clin Pharmacol Ther. 2009
   716 Dec;86(6):672–7.

- 717 12. Rurak D, Lim K, Sanders A, Brain U, Riggs W, Oberlander TF. Third Trimester Fetal Heart Rate and
- Doppler Middle Cerebral Artery Blood Flow Velocity Characteristics During Prenatal Selective
- Serotonin Reuptake Inhibitor Exposure. Pediatr Res. 2011 Jul;70(1):96–101.
- 720 13. Rotem-Kohavi N, Oberlander TF. Variations in Neurodevelopmental Outcomes in Children with 721 Prenatal SSRI Antidepressant Exposure. Birth Defects Res. 2017;109(12):909–23.
- The second of th
- 724 placental histopathology. J Perinatol. 2020 Jul;40(7):1017–24.
- 15. Clabault H, Flipo D, Guibourdenche J, Fournier T, Sanderson JT, Vaillancourt C. Effects of selective
- serotonin-reuptake inhibitors (SSRIs) on human villous trophoblasts syncytialization. Toxicol Appl
- 727 Pharmacol. 2018 Jun 15;349:8–20.
- 728 16. Clabault H, Cohen M, Vaillancourt C, Sanderson JT. Effects of selective serotonin-reuptake
- inhibitors (SSRIs) in JEG-3 and HIPEC cell models of the extravillous trophoblast. Placenta. 2018
- 730 Dec;72-73:62-73.
- 731 17. Thibeault AAH, de Los Santos YL, Doucet N, Sanderson JT, Vaillancourt C. Serotonin and serotonin
- reuptake inhibitors alter placental aromatase. J Steroid Biochem Mol Biol. 2019 Dec;195:105470.
- 733 18. Velasquez J, Goeden N, Bonnin A. Placental serotonin: implications for the developmental effects
- of SSRIs and maternal depression. Front Cell Neurosci. 2013;7:47.
- 735 19. Albert PR, Benkelfat C, Descarries L. The neurobiology of depression—revisiting the serotonin
- hypothesis. I. Cellular and molecular mechanisms. Philos Trans R Soc B Biol Sci. 2012 Sep
- 737 5;367(1601):2378-81.
- 738 20. Moncrieff J, Cooper RE, Stockmann T, Amendola S, Hengartner MP, Horowitz MA. The serotonin
- 739 theory of depression: a systematic umbrella review of the evidence. Mol Psychiatry. 2022 Jul 20;1–
- 740 14.
- 741 21. St-Pierre J, Laurent L, King S, Vaillancourt C. Effects of prenatal maternal stress on serotonin and
- 742 fetal development. Placenta. 2016 Dec;48 Suppl 1:S66–71.
- Honnin A, Goeden N, Chen K, Wilson ML, King J, Shih JC, et al. A transient placental source of
- serotonin for the fetal forebrain. Nature. 2011;472(7343):347–50.
- 745 23. Laurent L, Deroy K, St-Pierre J, Côté F, Sanderson JT, Vaillancourt C. Human placenta expresses
- both peripheral and neuronal isoform of tryptophan hydroxylase. Biochimie. 2017 Sep 1;140:159–
- 747 65.
- 748 24. Karahoda R, Abad C, Horackova H, Kastner P, Zaugg J, Cerveny L, et al. Dynamics of Tryptophan
- 749 Metabolic Pathways in Human Placenta and Placental-Derived Cells: Effect of Gestation Age and
- 750 Trophoblast Differentiation. Front Cell Dev Biol. 2020 Sep 18;8:574034.

- 751 25. Karahoda R, Robles M, Marushka J, Stranik J, Abad C, Horackova H, et al. Prenatal inflammation as
- a link between placental expression signature of tryptophan metabolism and preterm birth. Hum
- 753 Mol Genet. 2021 Jun 24;30(22):2053–67.
- 754 26. Campbell KSJ, Collier AC, Irvine MA, Brain U, Rurak DW, Oberlander TF, et al. Maternal Serotonin
- 755 Reuptake Inhibitor Antidepressants Have Acute Effects on Fetal Heart Rate Variability in Late
- 756 Gestation. Front Psychiatry. 2021 Aug 16;12:680177.
- 757 27. Laurent L, Huang C, Ernest SR, Berard A, Vaillancourt C, Hales BF. In utero exposure to venlafaxine,
- a serotonin-norepinephrine reuptake inhibitor, increases cardiac anomalies and alters placental
- and heart serotonin signaling in the rat. Birt Defects Res A Clin Mol Teratol. 2016
- 760 Dec;106(12):1044-55.
- 761 28. Dhar GA, Saha S, Mitra P, Nag Chaudhuri R. DNA methylation and regulation of gene expression:
- 762 Guardian of our health. The Nucleus. 2021 Dec 1;64(3):259–70.
- 763 29. Martin EM, Fry RC. Environmental Influences on the Epigenome: Exposure- Associated DNA
- Methylation in Human Populations. Annu Rev Public Health. 2018 Apr 1;39:309–33.
- 765 30. Chatterjee S, Ouidir M, Tekola-Ayele F. Genetic and in utero environmental contributions to DNA
- methylation variation in placenta. Hum Mol Genet. 2021 Nov 1;30(21):1968–76.
- 767 31. Vlahos A, Mansell T, Saffery R, Novakovic B. Human placental methylome in the interplay of
- adverse placental health, environmental exposure, and pregnancy outcome. PLOS Genet. 2019
- 769 Aug 1;15(8):e1008236.
- 32. Burton GJ, Fowden AL. The placenta: a multifaceted, transient organ. Philos Trans R Soc B Biol Sci.
- 771 2015 Mar 5;370(1663):20140066.
- 772 33. Pemathilaka RL, Reynolds DE, Hashemi NN. Drug transport across the human placenta: review of
- placenta-on-a-chip and previous approaches. Interface Focus. 2019 Oct 6;9(5):20190031.
- The state of Antidepressant Medications: 34. Ewing G, Tatarchuk Y, Appleby D, Kim D. Placental Transfer of Antidepressant Medications:
- 775 Implications for Postnatal Adaptation Syndrome. Clin Pharmacokinet. 2015 Apr;54(4):359–70.
- 776 35. Clifton VL. Review: Sex and the Human Placenta: Mediating Differential Strategies of Fetal Growth
- 777 and Survival. Placenta. 2010 Mar 1;31:S33–9.
- 778 36. Bale TL. Sex differences in prenatal epigenetic programing of stress pathways. Stress. 2011 Jul
- 779 1;14(4):348–56.
- 780 37. Bale TL. The placenta and neurodevelopment: sex differences in prenatal vulnerability. Dialogues
- 781 Clin Neurosci. 2016 Dec;18(4):459–64.
- 782 38. Gobinath AR, Workman JL, Chow C, Lieblich SE, Galea LAM. Sex-dependent effects of maternal
- corticosterone and SSRI treatment on hippocampal neurogenesis across development. Biol Sex
- 784 Differ. 2017 Jun 2;8:20.

- 785 39. Sutherland S, Brunwasser SM. Sex Differences in Vulnerability to Prenatal Stress: a Review of the Recent Literature. Curr Psychiatry Rep [Internet]. 2018 Nov [cited 2018 Oct 5];20(11). Available from: http://link.springer.com/10.1007/s11920-018-0961-4
- 788 40. Campbell KSJ, Williams LJ, Bjornson BH, Weik E, Brain U, Grunau RE, et al. Prenatal antidepressant exposure and sex differences in neonatal corpus callosum microstructure. Dev Psychobiol. 2021 Sep;63(6):e22125.
- 791 41. Rohan KJ, Rough JN, Evans M, Ho SY, Meyerhoff J, Roberts LM, et al. A Protocol for the Hamilton Rating Scale for Depression: Item Scoring Rules, Rater Training, and Outcome Accuracy with Data on its Application in a Clinical Trial. J Affect Disord. 2016 Aug;200:111–8.
- Murray D, Cox JL. Screening for depression during pregnancy with the edinburgh depression scale (EDDS). J Reprod Infant Psychol. 1990 Apr 1;8(2):99–107.
- Hair JD, Yuen RKC, Lim BK, McFadden DE, von Dadelszen P, Robinson WP. Widespread DNA
   hypomethylation at gene enhancer regions in placentas associated with early-onset pre-eclampsia.
   Mol Hum Reprod. 2013 Oct;19(10):697–708.
- 799 44. Paquette AG, Houseman EA, Green BB, Lesseur C, Armstrong DA, Lester B, et al. Regions of variable 800 DNA methylation in human placenta associated with newborn neurobehavior. Epigenetics. 2016 301 Jul 1;11(8):603–13.
- Kramer MS, Platt RW, Wen SW, Joseph KS, Allen A, Abrahamowicz M, et al. A new and improved
   population-based Canadian reference for birth weight for gestational age. Pediatrics. 2001
   Aug;108(2):E35.
- 46. Yuan V, Price EM, Del Gobbo G, Mostafavi S, Cox B, Binder AM, et al. Accurate ethnicity prediction from placental DNA methylation data. Epigenetics Chromatin. 2019 Aug 9;12(1):51.
- 47. Zhou W, Laird PW, Shen H. Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes. Nucleic Acids Res. 2017 Feb 28;45(4):e22.
- 809 48. Edgar RD, Jones MJ, Robinson WP, Kobor MS. An empirically driven data reduction method on the human 450K methylation array to remove tissue specific non-variable CpGs. Clin Epigenetics. 2017 Feb 2;9(1):11.
- 49. Dieckmann L, Cruceanu C, Lahti-Pulkkinen M, Lahti J, Kvist T, Laivuori H, et al. Reference-Based Versus Reference-Free Cell Type Estimation In DNA Methylation Studies Using Human Placental Tissue [Internet]. In Review; 2021 Sep [cited 2021 Dec 13]. Available from:
- 815 https://www.researchsquare.com/article/rs-848651/v1
- Pidsley R, Y Wong CC, Volta M, Lunnon K, Mill J, Schalkwyk LC. A data-driven approach to preprocessing Illumina 450K methylation array data. BMC Genomics. 2013 May 1;14:293.
- Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects
   and other unwanted variation in high-throughput experiments. Bioinformatics. 2012 Mar
   15;28(6):882–3.

 $821 \hspace{0.5cm} \textbf{52.} \hspace{0.5cm} \textbf{Nygaard V, R} \\ \textbf{Ødland EA, Hovig E. Methods that remove batch effects while retaining group} \\$ 

differences may lead to exaggerated confidence in downstream analyses. Biostatistics. 2016 Jan

- 823 1;17(1):29–39.
- Konwar C, Del Gobbo G, Yuan V, Robinson WP. Considerations when processing and interpreting genomics data of the placenta. Placenta. 2019 Sep;84:57–62.
- 54. Yuan V, Hui D, Yin Y, Peñaherrera MS, Beristain AG, Robinson WP. Cell-specific characterization of the placental methylome. BMC Genomics. 2021 Jan 6;22(1):6.
- 828 55. Lee Y, Choufani S, Weksberg R, Wilson SL, Yuan V, Burt A, et al. Placental epigenetic clocks:
- 829 estimating gestational age using placental DNA methylation levels. Aging. 2019 Jun
- 830 24;11(12):4238–53.
- Suarez A, Lahti J, Czamara D, Lahti-Pulkkinen M, Knight AK, Girchenko P, et al. The Epigenetic Clock
- at Birth: Associations With Maternal Antenatal Depression and Child Psychiatric Problems. J Am
- 833 Acad Child Adolesc Psychiatry. 2018 May;57(5):321-328.e2.
- 834 57. McKenna BG, Hendrix CL, Brennan PA, Smith AK, Stowe ZN, Newport DJ, et al. Maternal prenatal
- depression and epigenetic age deceleration: testing potentially confounding effects of prenatal
- stress and SSRI use. Epigenetics. 2021 Mar;16(3):327–37.
- 837 58. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression
- analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015 Apr 20;43(7):e47–
- 839 e47.
- 840 59. Bass A, Robinson D, Lianoglou S, Nelson E, Storey J, Gatto W. biobroom: Turn Bioconductor objects
- into tidy data frames. [Internet]. Available from: https://github.com/StoreyLab/biobroom
- 842 60. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach
- to Multiple Testing. J R Stat Soc Ser B Methodol. 1995;57(1):289–300.
- 844 61. Peters TJ, Buckley MJ, Statham AL, Pidsley R, Samaras K, Lord RV, et al. De novo identification of
- differentially methylated regions in the human genome. 2015;16.
- 846 62. Inkster AM, Yuan V, Konwar C, Matthews AM, Brown CJ, Robinson WP. A cross-cohort analysis of
- autosomal DNA methylation sex differences in the term placenta. Biol Sex Differ. 2021 May
- 848 27;12(1):38.
- 63. Gale CR, Marioni RE, Harris SE, Starr JM, Deary IJ. DNA methylation and the epigenetic clock in
- relation to physical frailty in older people: the Lothian Birth Cohort 1936. Clin Epigenetics. 2018
- 851 03;10(1):101.
- Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115.
- 853 65. Han LKM, Aghajani M, Clark SL, Chan RF, Hattab MW, Shabalin AA, et al. Epigenetic Aging in Major
- Depressive Disorder. Am J Psychiatry. 2018 Aug 1;175(8):774–82.

855 66. Tesfaye M, Chatterjee S, Zeng X, Joseph P, Tekola-Ayele F. Impact of depression and stress on placental DNA methylation in ethnically diverse pregnant women. Epigenomics. 2021 Sep;13(18):1485–96.

- 858 67. Non AL, Binder AM, Kubzansky LD, Michels KB. Genome-wide DNA methylation in neonates 859 exposed to maternal depression, anxiety, or SSRI medication during pregnancy. Epigenetics. 2014 860 Jul;9(7):964–72.
- 68. Cardenas A, Faleschini S, Cortes Hidalgo A, Rifas-Shiman SL, Baccarelli AA, DeMeo DL, et al.

  Prenatal maternal antidepressants, anxiety, and depression and offspring DNA methylation:
  epigenome-wide associations at birth and persistence into early childhood. Clin Epigenetics. 2019
  Mar 29;11(1):56.
- Kallak TK, Bränn E, Fransson E, Johansson Å, Lager S, Comasco E, et al. DNA methylation in cord blood in association with prenatal depressive symptoms. Clin Epigenetics. 2021 Dec;13(1):1–14.
- 70. DOCK10 [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004 [cited 2022 Mar 25]. Available from: https://www.ncbi.nlm.nih.gov/gene/55619.
- Ke-Niculescu H, Roseberry K, Gill SS, Levey DF, Phalen PL, Mullen J, et al. Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs.
   Mol Psychiatry. 2021 Jul;26(7):2776–804.
- 72. TSPAN2 [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004 [cited 2022 Mar 25]. Available from: https://www.ncbi.nlm.nih.gov/gene/10100.
- Kroeze Y, Peeters D, Boulle F, van den Hove DLA, van Bokhoven H, Zhou H, et al. Long-term consequences of chronic fluoxetine exposure on the expression of myelination-related genes in the rat hippocampus. Transl Psychiatry. 2015 Sep;5(9):e642–e642.
- 74. DGKA [Internet]. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004 [cited 2022 Mar 25]. Available from: https://www.ncbi.nlm.nih.gov/gene/1606.
- 882 75. Boroda S, Niccum M, Raje V, Purow BW, Harris TE. Dual activities of ritanserin and R59022 as DGKα inhibitors and serotonin receptor antagonists. Biochem Pharmacol. 2017 Jan 1;123:29–39.
- Sittler A, Wälter S, Wedemeyer N, Hasenbank R, Scherzinger E, Eickhoff H, et al. SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Mol Cell. 1998 Oct;2(4):427–36.
- Kang JY, Song SH, Yun J, Jeon MS, Cha Y, Lee SH, et al. Identification of Long-Range Epigenetic Silencing on Chromosome 15q25 and Its Clinical Implication in Gastric Cancer. Am J Pathol. 2015 Mar 1;185(3):666–78.

- 78. Axfors C, Bränn E, Henriksson HE, Hellgren C, Kunovac Kallak T, Fransson E, et al. Cohort profile: the Biology, Affect, Stress, Imaging and Cognition (BASIC) study on perinatal depression in a population-based Swedish cohort. BMJ Open. 2019 Oct 22;9(10):e031514.
- 79. Jaddoe VWV, Mackenbach JP, Moll HA, Steegers EAP, Tiemeier H, Verhulst FC, et al. The Generation R Study: Design and cohort profile. Eur J Epidemiol. 2006;21(6):475–84.

895



## **SSRI Model**

To assess the effect of SSRI Exposure in all cases, adjusting for mean maternal Hamilton Depression score

	SSRI-exposed (20)		SSRI non-exposed (44)	
Group	Maternally-depressed	Not maternally-depressed	Maternally-depressed	Not maternally-depressed
n	14	6	20	24
			<u></u>	<u> </u>

**SSRIs in Maternal Depression Model** 

To assess the effect of SSRI Exposure in maternally-depressed cases

**Maternal Depression without SSRIs Model** 

To assess the effect of Maternal Depression in SSRI non-exposed cases

